Antibody–drug conjugates drive growth in oncology
Antibody–drug conjugates are coming of age and pharma is investing, reports Katrina Megget
Pharma firms AstraZeneca and Daiichi Sankyo are betting on a new class of cancer drug known as antibody–drug conjugates or ADCs – and the firms are coming up trumps. In January, the partners’ drug Enhertu (trastuzumab deruxtecan) was approved by US regulators for HER2-positive gastric cancer, following the drug’s 2019 approval for HER2-positive breast cancer. Enhertu is deemed hot stuff – industry experts believe it could pull in upwards of $4 billion a year.